“…The cells were cultured on fibronectin-coated surfaces in chemically-defined, serum-free DMEM-Ham’s F12 medium containing insulin, transferrin, selenium, aprotinin, and human low-density lipoprotein as previously described (Markosyan et al 2006). The PTGFR agonist fluprostenol (1 μM; Cayman Chemical, Ann Arbor, MI), hCG (20 IU/ml, Sigma), the general cyclooxygenase inhibitor indomethacin (0.1 μM; Sigma), the phospholipase C (PLC) inhibitor U73122 (100 μM; Cayman), the protein kinase C (PKC) inhibitor Ro31-3220 (1 μM; CalBiochem, Billerica, MA), the mammalian target of rapamycin (mTOR) inhibitor rapamycin (1 μM; Invitrogen, Rockville, MD), the 3β-hydroxysteroid dehydrogenase inhibitor trilostane (250 ng/ml, Stegram Pharmaceuticals, Sussex, UK), progesterone (0.1 μM; Sigma), the aromatase inhibitor letrozole (4,4-[1,2,3-triazol-lyl-methylene]-bis-benzonitrite; 0.5 μM; Norvartis Pharm AG, Basel, Switzerland), estradiol benzoate (0.1 μM; Sigma), and the estrogen receptor antagonist ICI182,780 (1 μM; Tocris Biosciences, Bristol, UK) were added to cultures as indicated.…”